The AIM-HI Accelerator Fund congratulates our 2024 top winners led by aspiring women scientist-entrepreneurs. The winning early-stage oncology company of 2024 Women’s Venture Competition will be eligible to receive investment from AIM-HI and co-investors, subject to due diligence, which will serve as early seed money for proof of concept and proof of value on the path to clinical trials and, eventually, to new effective therapeutics that could save patients’ lives.

Ready to do more? DONATE NOW and help us double the impact for women scientist-entrepreneurs who are creating life-saving oncology innovations.